Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 Industry Snapshot
    • 2022 MA Life Sciences Workforce Analysis Report
    • 2021 State of Diversity, Equity, & Inclusion Report
    • Economic Development
    • Value of Health
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Domain Therapeutics NA Inc.

Life Sciences | Drug Development
Saint-Laurent, QC 514-375-2320 Website

Overview

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, with a subsidiary in Montreal, Quebec, Canada. It is dedicated to the discovery and early stage development of 1st in class G Protein-Coupled Receptors (GPCRs) / Transmembrane based drugs.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

•        The developement of collaborative partnerships with Pharma/Biotechs leveraging the knowledge and expertise of its R&D team and its two validated proprietary technologies BioSensAll™ (signalling signatures) and DTect-All™ (allosteric modulation)  

•        The development of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS, oncology and rare diseases through its own R&D and in-licensing external early-stage programmes

•        The valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2023 All Rights Reserved